keyword
MENU ▼
Read by QxMD icon Read
search

Prostate brachytherapy

keyword
https://www.readbyqxmd.com/read/28725242/focal-application-of-low-dose-rate-brachytherapy-for-prostate-cancer-a-pilot-study
#1
S Sara Mahdavi, Ingrid T Spadinger, Septimiu E Salcudean, Piotr Kozlowski, Silvia D Chang, Tony Ng, Julio Lobo, Guy Nir, Hamid Moradi, Michael Peacock, W James Morris
PURPOSE: To evaluate the feasibility and to report the early outcomes of focal treatment of prostate cancer using low-dose-rate brachytherapy (LDR-PB). MATERIAL AND METHODS: Seventeen patients were screened with multi-parametric magnetic resonance imaging (mpMRI), 14 of whom proceeded to receive trans-perineal template mapping biopsy (TTMB). Focal LDR-PB was performed on five eligible patients using dual air kerma strength treatment plans based on planning target volumes derived from cancer locations and determined by TTMB...
June 2017: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/28721888/long-term-quality-of-life-in-prostate-cancer-patients-treated-with-cesium-131
#2
Scott M Glaser, Katherine S Chen, Ronald M Benoit, Ryan P Smith, Sushil Beriwal
PURPOSE: To evaluate long-term patient-reported quality of life (QOL) scores in men with prostate cancer treated at our institution with (131)Cs prostate brachytherapy. METHODS AND MATERIALS: Patients treated more than 4 years ago with (131)Cs (n=290) were asked to fill out an Expanded Prostate Cancer Index Composite (EPIC) QOL questionnaire and American Urological Association Symptom Score (AUASS) survey, before treatment and at each follow-up appointment. We compared patients' EPIC and AUA scores at baseline with scores at a last follow-up of at least 4 years after treatment using the Wilcoxon signed-rank test...
August 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28721887/external-beam-radiation-therapy-with-a-brachytherapy-boost-versus-radical-prostatectomy-in-gleason-pattern-5-prostate-cancer-a-population-based-cohort-study
#3
Chenyang Wang, Amar U Kishan, Mitchell Kamrava, Michael L Steinberg, Christopher R King
PURPOSE: Patients with prostate cancer (PCa) containing Gleason pattern (GP) 5 disease experience a greater and earlier incidence of prostate cancer-specific mortality (PCSM) than general PCa patients. This affords the statistical power to compare PCSM outcomes among different treatment modalities even when restricting the analysis to patients treated in the modern era. The purpose of the present study was to compare the survival outcomes among patients with GP 5 PCa on needle core biopsy or transurethral resection of the prostate who underwent extremely dose-escalated radiation therapy (RT; exemplified by external beam RT with a brachytherapy boost [EBRT + BT]) versus radical prostatectomy (RP) in the modern era...
August 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28712786/the-relationship-between-hot-flashes-and-testosterone-recovery-after-12-months-of-androgen-suppression-for-men-with-localised-prostate-cancer-in-the-ascende-rt-trial
#4
M Dosani, W J Morris, S Tyldesley, T Pickles
AIMS: This study describes the proportion of men who experienced hot flashes (flashes), and the testosterone level at onset, peak frequency and cessation of flashes after 12 months of androgen deprivation therapy (ADT) in men undergoing curative-intent external beam radiation therapy (± brachytherapy boost). We also aimed to characterise testosterone recovery in this population. MATERIALS AND METHODS: This was a pre-specified secondary analysis of the ASCENDE-RT clinical trial...
July 13, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28710895/erectile-function-after-stereotactic-body-radiotherapy-for-localized-prostate-cancer
#5
Robert T Dess, Holly E Hartman, Nima Aghdam, William C Jackson, Payal D Soni, Ahmed E Abugharib, Simeng Suy, Neil B Desai, Zachary S Zumsteg, Rohit Mehra, Todd M Morgan, Felix Y Feng, Daniel A Hamstra, Matthew J Schipper, Sean P Collins, Daniel E Spratt
OBJECTIVE: To elucidate the functional erection rate following prostate stereotactic body radiotherapy (SBRT) and to develop a comprehensive prognostic model of outcomes following treatment. PATIENTS AND METHODS: Between 2008 and 2013, 373 consecutive men with localized prostate cancer were treated with SBRT at a single academic institution as part of a prospective clinical trial or prospective registry. Prospective longitudinal patient-reported quality of life (HRQOL) was collected using the Expanded Prostate Cancer Index Composite (EPIC-26)...
July 15, 2017: BJU International
https://www.readbyqxmd.com/read/28695317/pre-radiotherapy-psa-progression-is-a%C3%A2-negative-prognostic-factor-in-prostate-cancer-patients-using-5%C3%A2-alpha-reductase-inhibitors
#6
Daniel Taussky, Julie Piotte, Kevin C Zorn, Marc Zanaty, Vimal Krishnan, Carole Lambert, Jean-Paul Bahary, Marie-Claude Beauchemin, Maroie Barkati, Cynthia Ménard, Guila Delouya
OBJECTIVE: To investigate the impact of 5‑alpha-reductase inhibitor (5-ARI) use on radiotherapy outcomes for localized prostate cancer. PATIENTS AND METHODS: We included 203 patients on a 5-ARI from our institutional database comprising over 2500 patients who had been treated with either external beam radiotherapy (EBRT) or brachytherapy for localized prostate cancer. Patients received a 5-ARI for urinary symptoms or active surveillance. Cancer progressions at the time of definitive treatment were analyzed according to the following criteria: (a) progression of Gleason score or increase in cancer volume on biopsy, (b) first biopsy positive for cancer after being treated for urinary symptoms with a 5-ARI, and (c) prostate-specific antigen (PSA) progression with or without a previous cancer diagnosis...
July 10, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28688613/brachytherapy-boost-utilization-and-survival-in-unfavorable-risk-prostate-cancer
#7
Skyler B Johnson, Nataniel H Lester-Coll, Jacqueline R Kelly, Benjamin H Kann, James B Yu, Sameer K Nath
BACKGROUND: There are limited comparative survival data for prostate cancer (PCa) patients managed with a low-dose rate brachytherapy (LDR-B) boost and dose-escalated external-beam radiotherapy (DE-EBRT) alone. OBJECTIVE: To compare overall survival (OS) for men with unfavorable PCa between LDR-B and DE-EBRT groups. DESIGN, SETTING, AND PARTICIPANTS: Using the National Cancer Data Base, we identified men with unfavorable PCa treated between 2004 and 2012 with androgen suppression (AS) and either EBRT followed by LDR-B or DE-EBRT (75...
July 5, 2017: European Urology
https://www.readbyqxmd.com/read/28678408/longitudinal-regret-after-treatment-for-low-and-intermediate-risk-prostate-cancer
#8
Lauren M Hurwitz, Jennifer Cullen, Daniel J Kim, Sally Elsamanoudi, Jane Hudak, Maryellen Colston, Judith Travis, Huai-Ching Kuo, Kevin R Rice, Christopher R Porter, Inger L Rosner
BACKGROUND: Prostate cancer patients diagnosed with low- and intermediate-risk disease have several treatment options. Decisional regret after treatment is a concern, especially when poor oncologic outcomes or declines in health-related quality of life (HRQoL) occur. This study assessed determinants of longitudinal decisional regret in prostate cancer patients attending a multidisciplinary clinic and treated with radical prostatectomy (RP), external beam radiation therapy (EBRT), brachytherapy (BT), or active surveillance (AS)...
July 5, 2017: Cancer
https://www.readbyqxmd.com/read/28670842/long-term-oncological-outcomes-and-toxicity-in-597-men-%C3%A2-60-years-of-age-at-time-of-low-dose-rate-brachytherapy-for-localised-prostate-cancer
#9
Stephen E M Langley, Ricardo Soares, Jennifer Uribe, Santiago Uribe-Lewis, Julian Money-Kyrle, Carla Perna, Sara Khaksar, Robert Laing
OBJECTIVES: To report oncological and functional outcomes of men treated with low dose rate (LDR) prostate brachytherapy who were 60 years old or younger at time of treatment. PATIENTS AND METHODS: Of 3,262 patients treated with LDR brachytherapy at our centre up to June 2016, we retrospectively identified 597 patients ≤60 years at treatment with at least three years post-implant follow-up and four PSA measurements of which one was the baseline. Overall disease-specific and relapse-free survival were analysed together with prospectively collected physician reported adverse events and patient reported symptom scores...
July 3, 2017: BJU International
https://www.readbyqxmd.com/read/28666552/single-dose-high-dose-rate-brachytherapy-compared-to-two-and-three-fractions-for-locally-advanced-prostate-cancer
#10
Peter Hoskin, Ana Rojas, Peter Ostler, Robert Hughes, Roberto Alonzi, Gerry Lowe
BACKGROUND: Single-dose high-dose-rate brachytherapy (HDR-BT), in a Phase-II study, was compared to two or three fractions in intermediate and high-risk localized prostate cancer. PATIENTS AND METHODS: 293 patients received 1×19Gy or 1×20Gy (A=49), 2×13Gy (B=138), or 3×10.5Gy (C=106) and assessed with prospective measures of serum PSA, late genitourinary (GU) and gastrointestinal (GI) morbidity using RTOG scales and the International Prostate Symptom Score (IPSS)...
June 27, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28664931/the-evolution-of-brachytherapy-for-prostate-cancer
#11
REVIEW
Nicholas G Zaorsky, Brian J Davis, Paul L Nguyen, Timothy N Showalter, Peter J Hoskin, Yasuo Yoshioka, Gerard C Morton, Eric M Horwitz
Brachytherapy (BT), using low-dose-rate (LDR) permanent seed implantation or high-dose-rate (HDR) temporary source implantation, is an acceptable treatment option for select patients with prostate cancer of any risk group. The benefits of HDR-BT over LDR-BT include the ability to use the same source for other cancers, lower operator dependence, and - typically - fewer acute irritative symptoms. By contrast, the benefits of LDR-BT include more favourable scheduling logistics, lower initial capital equipment costs, no need for a shielded room, completion in a single implant, and more robust data from clinical trials...
June 30, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28664300/brachytherapy-in-the-treatment-of-breast-cancer
#12
REVIEW
Xinna Deng, Haijiang Wu, Fei Gao, Ye Su, Qingxia Li, Shuzhen Liu, Jianhui Cai
Brachytherapy is an important radio-therapeutic modality for a variety of malignancies, including prostate cancer, cervix cancer, breast cancer, vagina cancer, endometrium cancer, head and neck cancer, and many more. This technique has been shown to be an effective and safe non-pharmaceutical treatment with fewer serious complications and better outcome than other treatments for breast cancer. Every year, hundreds of thousands of patients around the world benefit from brachytherapy, which reliably delivers a relatively higher radiation dose to the intended target...
June 29, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28662788/clinical-issues-july-2017
#13
Mary J Ogg, Esther M Johnstone
Operation of fluoroscopy equipment Key words: fluoroscopy, mini C-arm, scope of practice, radiologic device. Patient education after radionuclide implantation Key words: radionuclides, brachytherapy, prostate cancer, radiation safety. Personal protective equipment Key words: clean, decontamination, instruments, PPE, tray assembly. Safe staffing patterns Key words: on-call staffing, schedules, safe staffing levels. Counting instruments when laparoscopy procedures convert to open procedures Key words: counts, instrument, laparoscopy, retained surgical items...
July 2017: AORN Journal
https://www.readbyqxmd.com/read/28652453/predictive-factors-for-prolonged-urination-disorder-after-permanent-125-i-brachytherapy-for-localized-prostate-cancer
#14
Hidehisa Mori, Tomoharu Fukumori, Kei Daizumoto, Megumi Tsuda, Yoshihito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima, Hiro-Omi Kanayama
BACKGROUND: We assessed the change in LUTS after prostate brachytherapy to reveal factors for prolonged urination disorder. MATERIALS AND METHODS: Four hundred and four patients received prostate brachytherapy at our institution and were followed-up for at least 2 years. We evaluated the correlation of mean IPSS changes and clinical factors. Using multivariate analysis, we also evaluated clinical factors with potential to delay IPSS resolution. RESULTS: In cases with prostate volume more than 30 cm(3), radiation dose to 90% of prostate volume (D90) more than 160 Gy, and radiation dose to 30% of the urethral volume (UD30) more than 240 Gy, mean IPSS levels were significantly higher, even 30 months after treatment...
July 2017: In Vivo
https://www.readbyqxmd.com/read/28652094/high-dose-rate-brachytherapy-boost-for-prostate-cancer-treatment-different-combinations-of-hypofractionated-regimens-and-clinical-outcomes
#15
Eric Vigneault, Khaly Mbodji, Sindy Magnan, Philippe Després, Marie-Claude Lavallée, Sylviane Aubin, Luc Beaulieu, William Foster, André-Guy Martin
PURPOSE: To report the outcomes of our high-dose-rate brachytherapy (HDR-BT) boost experience in localized prostate cancer treated with different combinations of radiation doses and fractionation. MATERIAL AND METHODS: Between 1999 and 2011, 832 patients were treated with different regimens of external beam radiotherapy (EBRT) and HDR-BT. These regimens were converted into three biologically effective dose (BED) groups. The biochemical failure-free survival (BFFS), reported with the phoenix definition and prostate-specific antigen (PSA) >0...
June 23, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28651992/-evaluation-of-the-french-practices-in-brachytherapy-using-surveys
#16
B Delattre, L Cormier, C Borgogno, J L Descotes, D Peiffert, J M Hannoun-Levi, J L Moreau
INTRODUCTION: Prostate cancer brachytherapy can be used as an alternative to the radical prostatectomy and radiotherapy. In the low-risk group, specific survivals are up to 95% after 10years. The aim of the study is to describe the practices in brachytherapy in France. MATERIALS AND METHODS: A survey made by AFU (French Urologic Association) and SFRO (French Society Of Oncological Radiotherapy) assessing the practices in brachytherapy in France was sent to all the urologists and radiotherapists even if they did not practice it...
June 23, 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/28648486/focal-brachytherapy-for-localized-prostate-cancer-urinary-toxicity-depends-on-tumor-location
#17
Victor Srougi, Eric Barret, Igor Nunes-Silva, Mohammed Baghdadi, Silvia Garcia-Barreras, Noelle Pierrat, Francois Rozet, Marc Galiano, Rafael Sanchez-Salas, Xavier Cathelineau, Jean-Marc Cosset
PURPOSE: To evaluate whether patients with prostate cancer have worse functional urinary recovery with focal brachytherapy (FBT) at the base versus the apex of the prostate. METHODS AND MATERIALS: The functional outcomes of patients treated with FBT at the base of the prostate were compared with those of patients treated with FBT at the apex. Urinary symptoms, continence, and erectile dysfunction were measured using the International Prostate Symptom Score (IPSS), International Continence Score (ICS), and International Index of Erectile Function (IIEF-5) questionnaires, respectively, at baseline and at 6, 12, and 24 months after treatment...
June 22, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28647400/intraoperative-registered-ultrasound-and-fluoroscopy-iruf-for-dose-calculation-during-prostate-brachytherapy-improved-accuracy-compared-to-standard-ultrasound-based-dosimetry
#18
Junghoon Lee, Omar Y Mian, Yi Le, Hee Joon Bae, E Clif Burdette, Theodore L DeWeese, Jerry L Prince, Daniel Y Song
BACKGROUND AND PURPOSE: Intraoperative transrectal ultrasound dosimetry during low-dose-rate prostate brachytherapy is imprecise due to sonographic distortion caused by seed echoes and needle tracks that obscure seed positions or create false signals as well as traumatic edema. Here we report the results of a pilot study comparing a combined ultrasound and fluoroscopy-based seed localization method (iRUF) to standard ultrasound-based dosimetry (USD). MATERIAL AND METHODS: Eighty patients undergoing permanent Pd-103 seed implantation for prostate cancer were prospectively enrolled...
June 21, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28646937/comparison-of-external-beam-radiotherapy-versus-permanent-seed-brachytherapy-as-monotherapy-for-intermediate-risk-prostate-cancer-a-single-center-canadian-experience
#19
Guila Delouya, Carole Lambert, Jean-Paul Bahary, Marie-Claude Beauchemin, Maroie Barkati, Cynthia Ménard, Daniel Taussky
INTRODUCTION: We tested different classification systems in order to separate intermediate-risk prostate cancers into prognostic groups. We then examined which groups were most suited for either prostate seed brachytherapy (PB) or external beam radiotherapy (EBRT). MATERIALS AND METHODS: We selected patients with D'Amico intermediate-risk prostate cancer who were treated exclusively with either PB or EBRT. Patients were excluded if they had received androgen deprivation therapy in combination with EBRT or a follow up of < 30 months without recurrence...
June 2017: Canadian Journal of Urology
https://www.readbyqxmd.com/read/28642046/prostate-specific-antigen-percentage-an-early-predictive-tool-after-iodine-125-interstitial-brachytherapy-for-prostate-cancer
#20
Mauro Paoluzzi, Andrea Losa, Valentina Cerboneschi, Caterina Colosimo, Nicola Fontana, Paola Mangili, Marcello Mignogna, Luciano Nava, Valentina Ravaglia
BACKGROUND: After interstitial prostate iodine-125 brachytherapy (BT), prostate-specific antigen (PSA) evolution in time could predict overall biochemical relapse, but, considering the single patient, it is influenced by the presentation PSA amount and by the prostatic volume. It is also challenging to differentiate a PSA bounce from a biochemical relapse. PURPOSE: To determine the usefulness of PSA percentage (PP) defined as the rate between PSA presented by a patient at time "t" and the PSA that the same patient had presented at the time of diagnosis (t0) assumed as 100% in predicting biochemical relapse and in differentiating them from PSA Bounces...
June 19, 2017: Brachytherapy
keyword
keyword
83387
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"